Expanding Global Access to ARVs:The Challenges of Prices and Patents

The AIDS Pandemic

Volumn , Issue , 2005, Pages 324-350

  Reich, Michael R ^a   Bery, Priya ^b  

^a HARVARD CENTER FOR POPULATION AND DEVELOPMENT STUDIES   (United States)

^b Knowledge Evaluation and Performance   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882838028     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012465271-2/50016-9     Document Type: Chapter

References (69)

1. Associated Press Brazil to build AIDS drug factory in Mozambique. 5 November 2003, http://www.aegis.com/news/ap/2003/AP031107.html.
2. Attaran A, Gillespie-White L Do patents constrain access to AIDS treatment in poor countries? Antiretroviral drugs in A frica. JAMA 2001, 286:1886-1892.
3. Boelaert M, Lynen L, Van Damme W, Colebunders R Do patents prevent access to drugs for HIV in developing countries? Letter. JAMA 2002, 287:840-841.
4. Caldwell JC Rethinking the African AIDS epidemic. Population Dev Rev 2000, 26:117-135.
5. Commission on Intellectual Property Rights Integrating Intellectual Property Rights and Development Policy 2002, September. Commission on Intellectual Property Rights, London.
6. Daniels N How to achieve fair distribution of ARTs in 3×5: Fair process and legitimacy in patient selection. Background paper for WHO/unaids Consultation on Equitable Access to Care for HIV/AIDS, Geneva, 26-27 January 2004.
7. Danzon P Making sense of drug prices. Regulation 2000, 23:56-63.
8. Danzon PM, Kim JD International price comparisons for pharmaceuticals: Measurement and policy issues. Pharmacoeconomics 1998, 14(Suppl):115-128.
9. DiMasi JA, Hansen RW, Grabowski HG The price of innovation: New estimates of drug development costs. J Health Econ 2003, 22:151-185.
10. Europe's addiction. Wall Street Journal 2002, Editorial, 2 January.
11. Freedberg K, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001, 344:824-831.
12. Friedman MA, den Bensten H, Attaran A Out-licensing: a practical approach for improvement of access to medicines in poor countries. Lancet 2003, 361:341-344.
13. Gilbert J, Rosenberg P Imbalanced Innovation. Presented at the World Economic Forum at Davos 2004, (accessed 7 March 2004), Bain & Company, Boston, MA. http://www.bain.com/bainweb/PDFs/cms/Marketing/addressing_innovation_div ide.pdf.
14. Global Business Coalition on HIV/AIDS nine major companies commit to coinvestment to expand community HIV/AIDS programs using corporate infrastructure 2003, 3 December, GBC, New York. http://www.businessfightsaids.org/news_read.asp?sct=2&ID=9202&PR =1.
15. Global Drug Facility GDF Factsheet 2001, (accessed 3 March 2002). http://www.stoptb.org/GDF/whatis/docs.
16. Grabowski G Patents, innovation and access to new pharmaceuticals. Int Econ Law 2002, 5:849-860.
17. Grace C Equitable Pricing of Newer Essential Medicines for Developing Countries: Evidence for the Potential of Different Medicines 2003, and Geneva: World Health Organization, Department for International Development, London. http://www.who.int/medicines/library/par/equitable_pricing.doc.
18. Hardwick C Access to medicines in the developing world through partnerships. Background paper for the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs 2001.
19. IMS Health Projected global pharmaceutical market by year 2002 2002, http://www.ims-global.com/insight/report/global/report.htm.
20. Public/Private Partnerships: Industry Contributions to Improving Access to Medicines in the Developing World 2001, (accessed 11 February 2002), IFP MA (International Federation of Pharmaceutical Manufacturers Associations)IFP MA (International Federation of Pharmaceutical Manufacturers Associations), IFPMA, Geneva. http://www.ifpma.org/PPPs.htm.
21. IFPMA Expanded Access to AIDS Medicines: Initiatives of the R&D-Based Pharmaceutical Industry 2003, IFPMA, Geneva.
22. IFPMA Position statement on intellectual property and patents 2004, (accessed 15 February 2004). http://www.ifpma.org/Issues/issues_intell.aspx.
23. Lanjouw JO A Patent Policy Proposal For Global Disease 2001, Policy Brief no. 84, The Brookings Institution, Washington DC.
24. Lanjouw JO Intellectual Property and the Availability of Pharmaceuticals in Poor Countries. Innovation Policy and the Economy 2003, 3:91-130. MIT Press.
25. Lei no 9.313.996, Aceso Universal a Terapia Anti-Retroviral no Sistema Publica de Saude.
26. McNeil D Indian company offers to supply AIDS drugs at low cost in A frica. New York Times 2001, 7 February.
27. Médecins Sans Frontières Untangling the Web of Price Reductions 2003, (accessed May 2003). http://www.accessmedmsf.org.
28. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients with HIV-1. Lancet 1998, 352:1725-1730.
29. Okero FA, Aceng E, Madraa E, et al. Scaling Up Antiretroviral Therapy: Experience in Uganda: Case Study 2003, World Health Organization, Geneva.
30. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
31. Park RS The international drug industry: What the future holds for South Africa's HIV/AIDS patients. Minnesota J Global Trade 2002, 11:125-154.
32. Industry Profile 2003 2003, PhRMA (Pharmaceutical Research Manufacturers Association). http://www.phrma.org/publications/publications/profile02/index.cmf.
33. Quick J Ensuring access to essential drugs-framework for action. Presentation at the WHO/WTO Workshop on Differential Pricing and Financing of Essential Drugs 2001.
34. Rapp T, Rozek R Benefits and costs of intellectual property protection in developing countries. J World Trade 1990, 24:75-102.
35. Reich MR Why the Japanese don't export more pharmaceuticals: Health policy as industrial policy. Calif Manage Rev 1990, 32:124-150.
36. Reuters GlaxoSmithKline Gives AIDS Drug Rights to Generic Maker. New York Times 2001, C-4. 9 October.
37. Rich JL, Petersen M Brazil will defy patent on AIDS drug made by Roche. New York Times 2001, 23 August.
38. Roberts MJ, Breitenstein AG, Roberts CS The ethics of public-private partnerships. Public-Private Partnerships for Public Health 2002, 67-85. distributed by Harvard University Press, Harvard Center for Population and Development Studies, Cambridge, MA. M.R. Reich (Ed.).
39. Roberts MJ, Hsiao W, Berman P, Reich MR Getting Health Reform Right: A Guide to Improving Performance and Equity 2004, Oxford University Press, New York.
40. Rose DN AIDS drug regimens that are worth their costs. JAMA 1998, 279:160-161.
41. Rosenberg T Look at Brazil. New York Times Magazine 2001, 26. 28 January.
42. Schoofs M Clinton program would help poor nations get AIDS drugs. Wall Street Journal 2003, 23 October.
43. Sherer FM, Watal J Post-TRIPS options for access to patented medicines in developing countries. CMH Working Paper Series 2001, (No. WG 4). 1, June.
44. Sidley P Drug companies withdraw law suit against South Africa. BMJ 2001, 322:1011.
45. Teixeira PR, Vitória MA, Barcarolo J The Brazilian experience in providing universal access to antiretroviral therapy. Economics of AIDS and Access to HIV/AIDS Care in Developing Countries: Issues and Challenges 2003, 69-88. ANRS, Collection Sciences Sociales et Sida, Paris.
46. Ulik J Canada drug crackdown-buying cheap drugs north of the border may become more difficult. CNN Money 2003, 13 March. http://money.cnn.com/2003/03/13/news/drugs_canada.
47. unaids Accelerating Access to HIV/AIDS Care and Treatment in Developing Countries: A Joint Statement of Intent. Final Draft 2000, 8 May, unaids, Geneva.
48. unaids Report on the Global Epidemic: Care and Support for People Living with HIV/AIDS 2000, June. unaids, Geneva.
49. unaids Report on the Global Epidemic: Table of Country-specific HIV/AIDS Estimates 2000, June. unaids, Geneva. http://www.unaids.org/epidemic_update/report/index.
50. unaids Accelerating Access to HIV/AIDS Care, Treatment and Support. Progress Report Updated November 2001 2001, unaids, Geneva. http://www.unaids.org/acc_access/Aaprogress1101.doc.
51. unaids/WHO AIDS Epidemic Update: 2003 2003, December. (unaids/03.39E), unaids/WHO, Geneva.
52. UNDP (United Nations Development Programme) Human Development Report 2001: Making New Technologies Work for Human Development 2001, UNDP, New York.
53. UNICEF-unaids Secretariat, WHO/HTP, MSF Sources and Prices of Selected Drugs and Diagnostics for People Living with HIV/AIDS Geneva 2001, May.
54. United States Trade Representative Foreign Barriers to Trade 2000, March. USTR, Washington, DC. http://www.ustr.gov/pdf/nte2000.pdf.
55. van der Vijver DAMC, et al. Analysis of more than 1600 newly diagnosed patients with HIV from 17 European countries shows that 10 per cent of the patients carry primary drug resistance: The CATCH study. Second International AIDS Society Conference, Paris, France, late breaker 1. Program and abstracts of the 2nd IAS Conference on HIV pathologenesis and Treatment. Abstract LB1 2003.
56. Viramune Donation Programme (accessed 11 February 2002). http://www.viramune-donation.
57. World Bank World Development Indicators 2000 2000, figure 2.14, World Bank, Washington, DC.
58. World Bank Brazil: World Bank approves US$100 million for HIV/AIDS and STD control. News release no. 2003/406/LAC 2003, 27 June, World Bank, Washington, DC.
59. WHO (World Health Organization) Health Reform and Drug Financing: Selected Topics 1998, (WHO/DAP/98.3), WHO, Geneva.
60. WHO Globalisation, TRIPS and Access to Pharmaceuticals. WHO Policy Perspectives on Medicines No. 3 2001, WHO, Geneva.
61. WHO Accelerating Access Initiative. Progress Report 2002, June. WHO, Geneva. http://www.who.int/hiv/pub/prev_care/isbn9241025.pdf.
62. WHO Treating 3 Million by 2005: Making it Happen, The WHO Strategy 2003, WHO and unaids, Geneva.
63. WHO, UNICEF, unaids, and MSF Sources and Prices of Selected Medicines and Diagnostics for People Living with HIV/AIDS 2003, June. WHO, Geneva. http://www.who.int/medicines/organization/par/ipc/sources-prices.pdf.
64. WHO and WTO Secretariats Report of the Workshop on Differential Pricing and Financing of Essential Drugs 2001, 8-11 April, Norwegian Foreign Affairs Ministry, Global Health Council, Oslo.
65. WTO (World Trade Organization) Doha Declaration on the TRIPS Agreement and Public Health. WTO Doc. WT/MIN(01)/DEC/2 2001, 20 november, WTO, Geneva. http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm .
66. WTO TRIPS and Pharmaceutical Patents: Fact Sheet 2001, April. WTO, Geneva. http://www.wto.org/wto/english/tratop_e/trips/factsheet_pharm00_e.html.
67. WTO Decision Removes Final Patent Obstacle to Cheap Drug Imports 2003, Press Release 350/Rev. 1, 30 August, WTO, Geneva.
68. WTO Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health. General Council Decision of 30 August 2003 (WT/L/540) 2003.
69. Young B, Surrusco M Rx R&D Myths: The Case Against the Drug Industry's R&D Scare Card 2001, July. Public Citizen, Washington, DC. http://www.citizen.org/documents/ACFDC.PDF.